Vitenskapelig artikkel

• Vere Rose Megens; Peter Wessel Strandhagen; Erik Magnus Berntsen et al. (2026). The clinical Alzheimer's disease spectrum classified in the A/T/N framework with¹⁸F-Flutemetamol-Centiloid,¹⁸F-MK-6240-CenTauR, and¹⁸F-FDG-AD metaROI: a multicenter memory clinic observational study. (ekstern lenke)
• Lydia Boyle; Brice Sylvain Daniel Marty; Kristoffer Haugarvoll et al. (2026). Use of sensing technologies to assess sleep quality and physical activity levels in nursing home residents with dementia taking nightly psychotropic drugs for sleep disturbance: a cross-sectional study. (ekstern lenke)
• Lydia Boyle; Monica Patrascu; Bettina Elisabeth Franziska Husebø et al. (2025). Use of Digital Biomarkers from Sensing Technologies to Explore the Relationship Between Daytime Activity Levels and Sleep Quality in Nursing Home Residents with Dementia: A Proof-of-Concept Study. (ekstern lenke)
• Kristoffer Haugarvoll; R Rademakers; JM Kachergus et al. (2008). Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. (ekstern lenke)
• Lydia Boyle; Brice Sylvain Daniel Marty; Kristoffer Haugarvoll et al. (2025). Selecting a smartwatch for trials involving older adults with neurodegenerative diseases: A researcher's framework to avoid hidden pitfalls. (ekstern lenke)
• Geir Olve Skeie; Bente Müller; Kristoffer Haugarvoll et al. (2013). Parkinson disease: Associated disorders in the Norwegian population based incident ParkWest study. (ekstern lenke)
• Irene Hana Flønes; Pawel Szymon Sztromwasser; Kristoffer Haugarvoll et al. (2016). Novel SLC19A3 promoter deletion and allelic silencing in biotin-thiamine-responsive basal ganglia encephalopathy. (ekstern lenke)
• Kristoffer Haugarvoll; Laurence Bindoff (2011). A novel compound heterozygous tyrosine hydroxylase mutation (p.R441P) with complex phenotype. (ekstern lenke)
• Christian Dölle; Irene Hana Flønes; Gonzalo Sanchez Nido et al. (2016). Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. (ekstern lenke)
• Kristoffer Haugarvoll; Charalampos Tzoulis; Gia Tuong Thi Tran et al. (2014). Myoclonus-dystonia and epilepsy in a family with a novel epsilon-sarcoglycan mutation. (ekstern lenke)
• Johannes Jernqvist Gaare; Gonzalo Sanchez Nido; Pawel Szymon Sztromwasser et al. (2018). Rare genetic variation in mitochondrial pathways influences the risk for parkinson's disease. (ekstern lenke)
• Kristoffer Haugarvoll; Mathias Toft; L Skipper et al. (2009). Fine-mapping and candidate gene investigation within the PARK 10 locus. (ekstern lenke)
• Charalampos Tzoulis; Thomas Schwarzlmüller; Martin Biermann et al. (2016). Mitochondrial DNA homeostasis is essential for nigrostriatal integrity. (ekstern lenke)
• Brage Brakedal; Christian Dölle; Frank Riemer et al. (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. (ekstern lenke)
• Yasaman Pakdaman; Monica Sanchez Guixe; Rune Kleppe et al. (2017). In vitro characterization of six STUB1 variants in spinocerebellar ataxia 16 reveals altered structural properties for the encoded CHIP proteins. (ekstern lenke)
• Charalampos Tzoulis; Gia Tuong Thi Tran; Thomas Schwarzlmüller et al. (2013). Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations. (ekstern lenke)
• Novin Balafkan; Charalampos Tzoulis; Bernd Muller et al. (2012). Number of CAG repeats in POLG1 and its association with Parkinson disease in the Norwegian population. (ekstern lenke)
• Kristoffer Haugarvoll; ZK Wszolek; M Hutton (2007). The genetics of frontotemporal dementia. (ekstern lenke)
• Johannes Jernqvist Gaare; Gonzalo Sanchez Nido; Christian Dölle et al. (2020). Meta-analysis of whole-exome sequencing data from two independent cohorts finds no evidence for rare variant enrichment in Parkinson disease associated loci. (ekstern lenke)
• Mathias Toft; IF Mata; OA Ross et al. (2007). Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. (ekstern lenke)
• OA Ross; MG Heckman; AI Soto et al. (2008). Dopamine beta-hydroxylase-1021C > T association and Parkinson's disease. (ekstern lenke)
• Kristoffer Haugarvoll; Mathias Toft; OA Ross et al. (2007). ELAVL4, PARK10, and the Celts. (ekstern lenke)
• Jan Aasly; C Vilarino-Guell; JC Dachsel et al. (2010). Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. (ekstern lenke)
• OA Ross; Kristoffer Haugarvoll; JT Stone et al. (2007). Lack of evidence for association of Parkin promoter polymorphism (PRKN-258) with increased risk of Parkinson's disease. (ekstern lenke)
• C Wider; SJ Lincoln; MG Heckman et al. (2009). Phactr2 and Parkinson's disease. (ekstern lenke)
• Christina Heidemann Sundal; Matt C. Baker; Virginija Danylaité Karrenbauer et al. (2015). Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. (ekstern lenke)
• Geir Olve Skeie; Bernd Mueller; Kristoffer Haugarvoll et al. (2010). Differential Effect of Environmental Risk Factors on Postural Instability Gait Difficulties and Tremor Dominant Parkinson's Disease. (ekstern lenke)
• Kristoffer Haugarvoll; Stefan Johansson; Carlos E. Rodriguez et al. (2017). GBA2 mutations cause a Marinesco-Sjogren-like syndrome: Genetic and biochemical studies. (ekstern lenke)
• Bergithe Eikeland Oftedal; Alexander Hellesen; Martina Moter Erichsen et al. (2015). Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. (ekstern lenke)
• Mathias Toft; Kristoffer Haugarvoll; OA Ross et al. (2007). LRRK2 and Parkinson's disease in Norway. (ekstern lenke)
• Johannes Jernqvist Gaare; Christian Dölle; Brage Brakedal et al. (2023). Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease. (ekstern lenke)
• Simon Ulvenes Kverneng; Kjersti Eline Stige; Haakon Berven et al. (2025). Mitochondrial complex I deficiency occurs in skeletal muscle of a subgroup of individuals with Parkinson’s disease. (ekstern lenke)
• Gonzalo Sanchez Nido; Fiona Dick; Lilah Toker et al. (2020). Common gene expression signatures in Parkinson’s disease are driven by changes in cell composition. (ekstern lenke)
• Brage Brakedal; Charalampos Tzoulis; Ole-Bjørn Tysnes et al. (2021). NSAID use is not associated with Parkinson's disease incidence: A Norwegian Prescription Database study. (ekstern lenke)
• Brage Brakedal; Irene Hana Flønes; Simone B. C. Frizell Reiter et al. (2017). Glitazone use associated with reduced risk of Parkinson's disease. (ekstern lenke)
• C Wider; JC Dachsel; AI Soto et al. (2009). FGF20 and Parkinson's Disease: No Evidence of Association or Pathogenicity via alpha-Synuclein Expression. (ekstern lenke)
• Haakon Berven; Simon Ulvenes Kverneng; Erika Sheard et al. (2023). NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease. (ekstern lenke)
• Irit Titlestad; Kristoffer Haugarvoll; Stein-Erik Hafstad Solvang et al. (2024). Delirium is frequently underdiagnosed among older hospitalised patients despite available information in hospital medical records. (ekstern lenke)
• Omar Hikmat; Charalampos Tzoulis; Wui K. Chong et al. (2017). The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations. (ekstern lenke)
• Gonzalo Sanchez Nido; Christian Dölle; Irene Hana Flønes et al. (2018). Ultradeep mapping of neuronal mitochondrial deletions in Parkinson's disease. (ekstern lenke)
• Irene Hana Flønes; Erika Fernandez-Vizarra; Maria Lykouri et al. (2017). Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. (ekstern lenke)
• Omar Hikmat; Charalampos Tzoulis; Claus Klingenberg et al. (2017). The presence of anaemia negatively influences survival in patients with POLG disease. (ekstern lenke)
• Irene Hana Flønes; Kristoffer Haugarvoll; Christina Heidemann Sundal et al. (2015). En kvinne i 70-årene med langvarige gangvansker. (ekstern lenke)
• Kristoffer Haugarvoll; Stefan Johansson; Charalampos Tzoulis et al. (2013). MRI characterisation of adult onset alpha-methylacyl-coA racemase deficiency diagnosed by exome sequencing. (ekstern lenke)
• Lilah Toker; Gia T. Tran; Janani Sundaresan et al. (2021). Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain. (ekstern lenke)
• Kristoffer Haugarvoll; Mathias Toft; OA Ross et al. (2007). Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway. (ekstern lenke)
• Ole Tveiten; Geir Olve Skeie; Kristoffer Haugarvoll et al. (2013). Treatment in early Parkinson's disease: the Norwegian ParkWest study. (ekstern lenke)
• Hege Vefring; Kristoffer Haugarvoll; Ole-Bjørn Tysnes et al. (2010). The role of APOE alleles in incident Parkinson's disease. The Norwegian ParkWest Study. (ekstern lenke)
• Brage Brakedal; Lilah Toker; Kristoffer Haugarvoll et al. (2022). A nationwide study of the incidence, prevalence and mortality of Parkinson’s disease in the Norwegian population. (ekstern lenke)
• Bernd Mueller; J. Assmus; J. P. Larsen et al. (2013). Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease. (ekstern lenke)
• Charalompos Tzoulis; Tetyana Zayats; Per Knappskog et al. (2015). HTRA2 p.G399S in Parkinson disease, essential tremor, and tremulous cervical dystonia. (ekstern lenke)

Konferanseabstrakt

• Lydia Boyle; Bettina Elisabeth Franziska Husebø; Brice Sylvain Daniel Marty et al. (2024). Digital phenotyping for changes in activity at the end of life in people with dementia. (ekstern lenke)

Vitenskapelig litteraturgjennomgang

• Lydia Boyle; Lionel Giriteka; Brice Sylvain Daniel Marty et al. (2025). Activity and Behavioral Recognition Using Sensing Technology in Persons with Parkinson’s Disease or Dementia: An Umbrella Review of the Literature. (ekstern lenke)
• Kjersti Eline Stige; Simon Ulvenes Kverneng; Soumya Sharma et al. (2024). The STRAT-PARK cohort: A personalized initiative to stratify Parkinson's disease. (ekstern lenke)
• Omar Hikmat; Tom Eichele; Charalampos Tzoulis et al. (2017). Understanding the epilepsy in POLG related disease. (ekstern lenke)

Doktorgradsavhandling

• Irene Hana Flønes; Charalampos Tzoulis; Christian Dölle et al. (2019). Mitochondrial mechanisms in neurodegeneration. (ekstern lenke)

Leserbrev

• MJ Farrer; K Haugarvoll; OA Ross et al. (2006). Genomewide association, Parkinson disease, and PARK10. (ekstern lenke)
• Kristoffer Haugarvoll; Laurence Bindoff; Charalampos Tzoulis (2016). Nigrostriatal denervation sine parkinsonism. (ekstern lenke)
• C Vilarino-Guell; OA Ross; AI Soto et al. (2009). Reported Mutations in GIGYF2 are not a Common Cause of Parkinson's Disease. (ekstern lenke)
• Brage Brakedal; Kristoffer Haugarvoll; Charalampos Tzoulis (2017). Simvastatin is associated with decreased risk of Parkinson disease. (ekstern lenke)
• Johannes Jernqvist Gaare; Gonzalo Sanchez Nido; Pawel Szymon Sztromwasser et al. (2018). No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease. (ekstern lenke)

Rettelse i tidsskrift

• Omar Hikmat; Charalampos Tzoulis; Claus Klingenberg et al. (2017). Erratum to: The presence of anaemia negatively influences survival in patients with POLG disease (Journal of Inherited Metabolic Disease, (2017), 40, 6, (861-866), 10.1007/s10545-017-0084-9). (ekstern lenke)

Se en fullstendig oversikt over publikasjoner i NVA.